Concepedia

Erik Koenig

EK

12

Publications

1.7K

Citations

12

H-Index

1990

Active since

Affiliations

Takeda (United States)(Current)

Millennium Engineering and Integration (United States)

University of Pennsylvania

Dana-Farber Cancer Institute

Eli Lilly (United States)

Erik Koenig is an author at Takeda (United States) specializing in medicine, cell biology, and tumor biology.

ORCID

Top concepts

Publications per year

1990–2021

12

Publications

12

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

George Mulligan, Constantine S. Mitsiades, Barbara M. Bryant et al. · Blood · 2006 · 409 citations · Full text

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Michael A. Milhollen, Tary Traore, Jennifer Adams-Duffy et al. · Blood · 2010 · 320 citations · Full text

Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor

Xingyue He, Jessica Riceberg, Teresa A. Soucy et al. · Nature Chemical Biology · 2017 · 223 citations

, , +10

Trypanosoma brucei: constitutive activity of the VSG and procyclin gene promoters.

Étienne Pays, Hélène Coquelet, Patricia Tebabi et al. · The EMBO Journal · 1990 · 137 citations · Full text

, , +7

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

Eric S. Lightcap, Pengfei Yu, Stephen Grossman et al. · Science Translational Medicine · 2021 · 129 citations · Full text

Rows per page

1–5 of 12